AELIS Stock Overview
Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aelis Farma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.00 |
| 52 Week High | €14.10 |
| 52 Week Low | €12.80 |
| Beta | 0.12 |
| 1 Month Change | -2.62% |
| 3 Month Change | -2.99% |
| 1 Year Change | -7.80% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| AELIS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -0.2% |
| 1Y | -7.8% | -10.2% | 2.3% |
Return vs Industry: AELIS exceeded the French Biotechs industry which returned -10.2% over the past year.
Return vs Market: AELIS underperformed the French Market which returned 2.3% over the past year.
Price Volatility
| AELIS volatility | |
|---|---|
| AELIS Average Weekly Movement | 1.3% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.8% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: AELIS has not had significant price volatility in the past 3 months.
Volatility Over Time: AELIS's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 22 | Pier Piazza | www.aelisfarma.com |
Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.
Aelis Farma SA Fundamentals Summary
| AELIS fundamental statistics | |
|---|---|
| Market cap | €170.69m |
| Earnings (TTM) | -€5.08m |
| Revenue (TTM) | €12.36m |
13.8x
P/S Ratio-33.6x
P/E RatioIs AELIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AELIS income statement (TTM) | |
|---|---|
| Revenue | €12.36m |
| Cost of Revenue | €0 |
| Gross Profit | €12.36m |
| Other Expenses | €17.44m |
| Earnings | -€5.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 16, 2024
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 100.00% |
| Net Profit Margin | -41.09% |
| Debt/Equity Ratio | 25.2% |
How did AELIS perform over the long term?
See historical performance and comparison